News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DSM Pharmaceuticals, Inc. Products Forms Manufacturing Alliance With Galenix


11/5/2009 11:27:21 AM

PARSIPPANY, N.J., Nov. 5 /PRNewswire/ -- DSM Pharmaceutical Products today announced that it has made a manufacturing alliance with Galenix, Saint Jean D'Illac, France, where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.

Pieter de Geus, Senior Vice President, R&D stated, "These innovative drug delivery technologies enhance our offering in the field of pharmaceutical development services and complement our portfolio of drug delivery technologies. The collaboration with Galenix clearly demonstrates DSM's commitment to bringing improved drug delivery to markets globally."

Jerome Besse, CEO of Galenix concurred with the DSM comments, and further added, "This is truly a win-win situation. Galenix is privileged in working with DSM to generate value for our customers. The partnership fits with our strategic intention of expanding service offerings to the North America market, and also with DSM's expansion of sales & marketing focus in Europe."

Galenix

Founded in 1993 by CEO Jerome Besse, Galenix is ranked in the top European leaders for pharmaceutical R&D and drug delivery systems. Galenix provides comprehensive pharmaceutical development services to healthcare companies, from the sourcing of Active Pharmaceutical Ingredients (API's) to clinical supply services and regulatory submission. Its two major competitive strengths, in addition to a full service delivery, are the compliance of the cGMP facilities with European and American standards, as well as its extensive know-how and experience in patented, innovative drug delivery system design and drug product development. The Galenix drug delivery systems, providing improvement and better patient compliance of medicines, include Minextab(R) and Minextab(R) floating high-dosage tablet technologies; Microgix(R) bioavailability / solubility technology; Mucolys(R) film trans-mucosal absorption and Mucolys(R) flash sub-lingual absorption technologies; and the ODTx orodispersible /dispersible oral dosage technology with no need of water to ingest. More information: www.galenix.fr

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

CONTACT: DSM Pharmaceutical Products, Guy Tiene, Director Marketing and
Communications, +1-973-257-8160, guy.tiene@dsm.com

Web site: http://www.dsmpharmaceuticals.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES